The U.S. Food and Drug Administration today approved teclistamab in combination with daratumumab hyaluronidase-fihj, Tec-Dara, to treat adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy.
FDA News Releases published a clinical update in Research Highlights on 05 Mar 2026. The item focuses on FDA Grants Third Approval Under the National Priority Voucher Program. Open the detail page to review the full original feed content.